$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...
Hence then, the article about atossa therapeutics announces closing of registered direct offering of up to 16 5 million in gross proceeds was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds )
Also on site :
- Texas woman injured by McDonald’s Sausage McMuffin ‘wholly unfit for human consumption’: suit
- ‘House of Guinness’ Renewed for Season 2 by Netflix (EXCLUSIVE)
- Saudi Arabia plans freight rail corridor